Efficacy of MK0557 in Combination With Sibutramine or Orlistat

This study has been completed.

First Received on September 19, 2007. No Changes Posted

Sponsor:	Merck
Information provided by:	Merck
ClinicalTrials.gov Identifier:	NCT00533481

Purpose

Study medicine will be given alone, or in combination with either sibutramine or orlistat, to obese subjects to compare the effect on body weight over a six month period.

Condition	Intervention	Phase
Obesity	Drug: MK0557	Phase II

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Factorial Assignment Masking: Double-Blind Primary Purpose: Treatment

Resource links provided by NLM:

MedlinePlus related topics: Obesity

Drug Information available for: MK 0557

U.S. FDA Resources

Further study details as provided by Merck:

Study Start Date:	December 2003
Study Completion Date:	December 2003

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Men and women between the ages of 18-65 who are considered obese (have a body mass index between 30 and 43)

Exclusion Criteria:

Subject has high blood pressure or is taking any high blood pressure medicine
History of psychiatric disorder, stroke, or heart disease

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00533481

Sponsors and Collaborators

Merck

Investigators

Study Director:

Medical Monitor

Merck

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00533481 History of Changes
Other Study ID Numbers:	2007_615
Study First Received:	September 19, 2007
Last Updated:	September 19, 2007
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:

Obesity
Overnutrition
Nutrition Disorders

Overweight
Body Weight
Signs and Symptoms

ClinicalTrials.gov processed this record on February 09, 2012